Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Non-Current Debt (2018 - 2024)

Serina Therapeutics (SER) has disclosed Non-Current Debt for 7 consecutive years, with $693000.0 as the latest value for Q3 2024.

  • Quarterly Non-Current Debt changed 0.0% to $693000.0 in Q3 2024 from the year-ago period, while the trailing twelve-month figure was $693000.0 through Sep 2024, changed 0.0% year-over-year, with the annual reading at $10.5 million for FY2022, 72.85% up from the prior year.
  • Non-Current Debt hit $693000.0 in Q3 2024 for Serina Therapeutics, roughly flat from $693000.0 in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $10.5 million in Q4 2022 to a low of $693000.0 in Q3 2023.
  • Historically, Non-Current Debt has averaged $4.9 million across 5 years, with a median of $5.3 million in 2021.
  • Biggest five-year swings in Non-Current Debt: soared 1520.42% in 2020 and later plummeted 93.12% in 2024.
  • Year by year, Non-Current Debt stood at $3.9 million in 2020, then soared by 55.44% to $6.1 million in 2021, then soared by 72.85% to $10.5 million in 2022, then crashed by 93.39% to $693000.0 in 2023, then changed by 0.0% to $693000.0 in 2024.
  • Business Quant data shows Non-Current Debt for SER at $693000.0 in Q3 2024, $693000.0 in Q2 2024, and $693000.0 in Q1 2024.